February 10, 2012
MADERA, Calif.Polyphenolics, a division of Constellation Brands, has reported the U.S. Patent and Trademark Office (USPTO) has confirmed a fourth patent (no. 8,075,929) for its MegaNatural-BP grape seed extract (GSE). The patent covers the production process for the structurally unique GSE.
This patent provides an additional marketing edge and competitive advantage to products developed with MegaNatural-BP, which has greater bioavailability and absorption compared to other grape seed extracts, said Anil Shrikhande, Ph.D., president of Polyphenolics. Two placebo-controlled human clinical trials conducted by researchers at the Department of Preventive Cardiology, University of California Davis School of Medicine, have found that MegaNatural-BP supports blood pressure within the normal range. No other grape seed extract can say the same, since MegaNatural-BP has a un ique structure and composition.
You May Also Like
The rise of ashwagandha: A case study in a growing and evolving category – articleNov 28, 2023
Ashwagandha: Roots for wellness, leaves for soil – articleNov 28, 2023
Creatine, whey protein, beta-alanine among picks in NFL-style draft at SupplySide WestDec 01, 2023
Unleash the power of ‘combos’ supplements to meet consumer demand – infographicNov 22, 2023